FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - December 5, 2025 230 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR NHS England Lung Cancer Screening Programme Demonstrates that it is Feasible and Scalable... April 3, 2026 15% of People With Lung Cancer Have an Inherited Mutation for... August 15, 2022 ESMO awards its first fellowship to support digital and computational pathology September 10, 2025 Magnetic Fish-Shaped Microbots Deliver Chemotherapy to Exactly Where It’s Needed December 9, 2021 Load more HOT NEWS Colorectal Cancer Screening: Where Does the Shield Liquid Biopsy Fit In? FDA Grants Regular Approval to Sacituzumab Govitecan for Advanced Triple-Negative Breast... EMA Recommends Granting a Marketing Authorisation for Camizestrant EMA Recommends Extension of Therapeutic Indications for Olaparib to Patients with...
